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Prolactin (PRL) is a hormone with over 300 biolog-
ical activities. Although the signaling pathway
downstream of the long form of its receptor (RL)
has been well characterized, little is known about
PRL actions upon activation of the short form (RS).
Here, we show that mice expressing only RS ex-
hibit an ovarian phenotype of accelerated follicular
recruitment followed by massive follicular death
leading to premature ovarian failure. Conse-
quently, RS-expressing ovaries of young adults are
depleted of functional follicles and formed mostly
by interstitium. We also show that activation of RS
represses the expression of the transcription fac-
tor Forkhead box O3 (FOXO3) and that of the en-
zyme galactose-1-phosphate uridyltransferase
(Galt), two proteins known to be essential for nor-
mal follicular development. Our finding that FOXO3
regulates the expression of Galt and enhances its
transcriptional activity indicates that it is the re-
pression of FOXO3 by PRL acting through RS that
prevents Galt expression in the ovary and causes
follicular death. Coexpression of RL with RS pre-
vents PRL inhibition of Galt, and the ovarian defect
is no longer seen in RS transgenic mice that coex-
press RL, suggesting that RL prevents RS-induced
ovarian impairment. In summary, we show that
PRL signals through RS and causes, in the absence
of RL, a severe ovarian pathology by repressing the
expression of FOXO3 and that of its target gene
Galt. We also provide evidence of a link between
the premature ovarian failure seen in mice ex-
pressing RS and in mice with FOXO3 gene deletion
as well as in human with Galt mutation. (Molecular
Endocrinology 22: 513–522, 2008)
PROLACTIN (PRL) IS A polypeptide hormone thatwas originally identified by its ability to stimulate
mammary development and lactation. Although PRL is
involved in diverse biological processes, its actions on
reproductive processes represent the largest group of
functions identified for this hormone (1, 2). PRL is
produced in the lactotrophic cells of the anterior pitu-
itary gland as well as in other extrapituitary sites such
as the immune, decidual, mammary, epithelial, and fat
cells (3–5).
PRL signals through a membrane-bound receptor
(PRLR), member of the class 1 cytokine receptor su-
perfamily. PRLR gene generates by alternative splicing
different isoforms that are identical in their extracellu-
lar ligand-binding domain but differ in the length and
sequence of their intracellular domain (1). In human
and rodent, long (RL) and short (RS) forms of the PRLR
are differentially expressed in different tissues, sug-
gesting they may activate distinct signaling pathways
(6–10). PRL acting through RL activates many kinases
including Janus kinase 2/signal transducer and acti-
vator of transcription (11), steroid receptor coactivator
kinase (12, 13), phosphatidylinositol 3-kinase/protein
kinase B (14), and MAPK pathways (15). Although it
has been proposed that RS could behave either as a
dominant-negative isoform by inhibiting the function of
the RL (16–19) or as a positive regulator in mammary
gland (20), the mechanism by which PRL signals
through RS remains completely unknown. One of the
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most established functions of PRL in reproduction is
its key role in maintaining the ovarian corpus luteum
(CL) and progesterone production (21, 22). Indeed,
one of the defects seen in PRLR null females is an
early involution of the CL and infertility due to insuffi-
cient levels of progesterone to support implantation
and to maintain the uterus quiescent (23). Beside this
defect in the CL of pregnancy, PRLR null ovaries are
normal and do not present differences in either follic-
ular development or ovulation rate when compared
with wild types (24). Whereas PRL regulation of CL is
thought, but yet never proven, to be through activation
of RL (21, 22), the impact of RS activation on ovarian
development is not at all known.
For the present study, we have generated PRLR/
females overexpressing the RS as the only isoform of
the receptor, which makes this animal an ideal model
to examine the putative role of the RS in vivo. Our
results show, for the first time, that in absence of RL,
PRL signaling through RS causes a severe follicular
impairment that leads to premature ovarian failure
(POF). Furthermore, activation of RS induces down-
regulation of Forkhead transcription factor (FOXO3)
as well as galactose-1-phosphate uridyltransferase
(Galt), two molecules known to be critical for normal
ovarian development (25–27). Our results on FOXO3-
Galt interaction as well as their negative regulation by
PRL through RS provide a mechanism that mediates
the development of the acute ovarian defect displayed
by PRLR/RS transgenic females and also provide a
link to the similar POF displayed by the FOXO3 null
mice and by women with Galt mutation.
RESULTS
Effect of RS Expression on Follicular
Development
For the present study, we used females bearing a null
mutation in both alleles of the PRLR gene and over-
expressing a transgenic construct containing the
mouse PR-1 short isoform of the PRLR (PRLR/RS
mice). Because expression of this construct is driven
by the elongation factor 1 promoter, RS is ubiquitously
expressed in all cell types (supplemental Fig. 1, pub-
lished as supplemental data on The Endocrine Soci-
ety’s Journals Online web site at http://mend.
endojournals.org). These mice were generated by
crossing PRLR/RS females with fertile PRLR/
males (Fig. 1). PRLR/RS females are outwardly nor-
mal and do not present major differences in behavior,
body weight, or mortality rate as compared with
PRLR/ or PRLR/ animals (not shown). Of great
interest, however, was our finding that PRL signaling
through RS profoundly impacts follicular survival. Early
during development, PRLR/RS ovaries are larger
than those of PRLR/, and when treated with human
chorionic gonadotropin (hCG), they ovulate a signifi-
cantly greater number of oocytes than either the PRLR
null or the wild-type mice (Fig. 2A). At 2 months of age,
the number of secondary, preantral, and antral follicles
is markedly increased in PRLR/RS ovaries (Fig. 2B),
indicating that premature follicular development oc-
curs at an early age in these females. Interestingly,
however, a severe follicular death begins from 4 wk of
age, and by the time these PRLR/RS females are 4
months old, the ovaries appear severely pathological
(Fig. 2C). At this age, these females still cycle and
accept the male, yet they cannot be superovulated
(Fig. 3). Histological examination shows ovaries with
severe follicular impairment and numerous holes that
are the result of follicular death (Figs. 2C and 3C). In
those follicles that are in the process of degeneration
(Fig. 3D, upper panel), the mural granulosa cells are
disorganized and the oocytes devoid of cumulus.
Without the surrounding granulosa, the oocytes de-
generate and lose their content. Finally, the zona pel-
lucida collapses and remains surrounded by theca/
interstitial cells (Fig. 3D, upper panel). As PRLR/RS
females get older, (Figs. 2C and 3C), the ovaries are
almost completely depleted of functional follicles and
are formed mostly by theca and interstitial cells sur-
rounding numerous holes containing collapsed zona
pellucida that are the remnant of dead oocytes (Fig.
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Fig. 1. Mice Genotyping by RT-PCR
A, Females expressing only the short form of the prolactin
receptor (PRLR/RS) have been generated by mating
PRLR/RS females with fertile PRLR/ males. Arrows in-
dicate hybridization site for the primers used for genotyping.
B, PRLR/ females were obtained by mating PRLR/ fe-
males with PRLR/ males. C, Homozygous, heterozygous,
or null PRLR mRNA expression was detected by using prim-
ers for exon 5 and for neo cassette on genomic DNA sam-
ples. Expression of transgenic RS was detected by using
primers for the terminal block of human GH in the eF1-
PRLR-PR-1 transgenic construct.
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3D, lower panel). This likely reflects widespread follic-
ular initiation followed by follicular cell death.
Although morphologically the theca/interstitial cells
do not seem affected, expression of cytochrome P450
17-hydroxylase (P450c17), a key enzyme for andro-
gen biosynthesis, is completely absent in PRLR/RS
ovaries compared with PRLR/, indicating that acti-
vation of RS has also a negative impact on the steroi-
dogenic capacity of the theca/interstitial cells (Fig. 4A,
upper panel).
Early during development, PRLR/ as well as
PRLR/RS females ovulate and form CL of preg-
nancy; however, a regression of these CLs is seen
within 2.5 d, and pregnancy cannot be sustained. Both
genotypes show similar levels of apoptosis in the re-
gressing CLs (Fig. 4A, lower panel). Subcutaneous
implantation of progesterone pellets in PRLR/ and
PRLR/RS females allowed a partial rescue of em-
bryos with no significant differences between the two
genotypes (Fig. 4B). Because similar expression of
both isoforms were found in CL (7, 9), a role for RS on
CL was suggested (9). However, the inability of the RS
to rescue the CL in pregnant PRLR/RS females
clearly establishes a key role for RL in the PRL main-
tenance of a functionally progesterone-producing CL.
The absence of RL expression and the inability to
maintain the CL and pregnancy are probably the only
similarities between PRLR/ and PRLR/RS ova-
ries. In contrast to PRLR/RS, histological analysis of
PRLR/ ovaries shows normal follicular development
(Fig. 3B), suggesting that the follicular defect dis-
played by PRLR/RS ovaries is due entirely to acti-
vation and signaling through RS. Interestingly, RS
transgenic females that are wild type or heterozygous
for the PRLR gene (PRLR/RS or PRLR/RS) do
not present any sort of ovarian impairment. These
Follicular Dia me ter  (µ m) 
PRLR+/ + 
PRLR-/-R S 
50 
100 
150 
200 
250 
300 
prim ar y s  ec ondary 
an d p  re -a ntra l 
an tr al pre- 
ov ulat or y 
B
C
R
el
at
iv
e 
Fo
lli
cl
e 
C
ou
nt
 
R
el
at
iv
e 
O
oc
y t
e 
C
ou
nt
   
10 
20 
30 
40 
50 
60 
70 
PRLR      +/+       -/ - -  /- 
** 
A
RS               - -  +
PRLR+/ + P  RLR-/-RS 
<50 50 - 100 100 - 200  >200 
2 w  eek s 
+/ + - /-RS 
2 m  onth s 
4 m  onth s 
5 m  onth s 
Fig. 2. PRL Signaling through RS Accelerates Follicular Re-
cruitment
A, Superovulation was induced with eCG and hCG in
2-month-old PRLR/, PRLR/, and PRLR/RS mice; up-
per panel, average number of released oocytes per female
(n  10 animals per group; *, P  0.001); lower panel, gross
morphology of PRLR/ and PRLR/RS ovaries (note the
difference in the size at 2 months of age). B, Follicular devel-
opment in 2-month-old females: total primary (50 m), sec-
ondary and preantral (50–100 m), antral (100–200 m), and
preovulatory (200 m) follicles. C, Ovarian histology at dif-
ferent ages of cycling PRLR/ (left) and PRLR/RS (right)
ovaries. Sections were stained with hematoxylin-eosin.
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Fig. 3. PRL Signaling through RS Has a Deleterious Effect
on Follicular Development
A–C, Ovarian histology of PRLR/ (A), PRLR/ (B), and
PRLR/RS (C) of 4-month-old mice after superovulation
with eCG and hCG. All sections are stained with hematoxylin-
eosin. D, Ovarian histology of a cycling 5-month-old
PRLR/RS female shows follicles in different stages of de-
generation (upper panel). PRLR/RS ovaries 5 months and
older are formed mostly by theca/interstitial cells surrounding
holes that are remnants of dead follicles (lower panel).
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females are fertile and have normal litters. Although
they highly express RS, they display a normal follicular
development (Fig. 4C), suggesting that the RL re-
verses the detrimental effect of RS on follicular
development.
Even though no difference in the serum PRL levels
was found between PRLR/ and PRLR/RS fe-
males (Fig. 4D), both groups presented high PRL lev-
els as compared with wild-type females. These results
are in agreement with data previously reported for the
high circulating PRL in PRLR/ females (28) and sup-
port the finding that PRL through RL down-regulates
its own synthesis and/or secretion at the hypothalamic
and/or pituitary level (29).
Galt Expression Is Repressed by PRL Signaling
through RS
Microarray analysis performed with ovarian tissue
shows that PRL through RS significantly regulates the
expression of more than 80 genes that participate in
different biological processes such as immune re-
sponse, protein metabolism, transport, signal trans-
duction, and cell communication (the entire list of RS-
regulated genes can be found in supplemental Table
1). This shows that PRL indeed signals through RS in
the ovary and actively regulates the expression of
several genes. Interestingly, Galt, whose mutation was
shown to induce galactosemia and POF in women
(30), is down-regulated in PRLR/RS ovaries.
To further analyze the down-regulation of Galt by
RS, we examined Galt mRNA levels in ovaries of
PRLR/ and PRLR/RS mice by semiquantitative
RT-PCR. As shown in Fig. 5A, Galt expression is com-
pletely abolished in ovaries of PRLR/RS females in
contrast to their PRLR null littermates (Fig. 5A). We
also examined the ability of PRL to regulate Galt tran-
scription in a subclone of UIII cells (31) that does not
express any PRLR. Cells were transiently transfected
with Galt promoter-reporter vector and RS expression
vector. PRL treatment induced a marked decrease in
Galt promoter activity, indicating clearly that PRL act-
ing through RS represses the transcriptional activity of
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Fig. 4. Effect of PRL Signaling through RS on Theca, CL,
and Fetal Survival
A, Upper panel, Immunolocalization of P450c17 in 12-
month-old PRLR/ and PRLR/RS ovaries with immuno-
reactivity shown in red and hematoxylin-counterstained nu-
clei in blue; lower panel, apoptosis levels analyzed by
terminal deoxynucleotide transferase-mediated nick end-la-
beling in PRLR/ and PRLR/RS CL. Reactivity is shown in
brown and hematoxylin-counterstained nuclei in blue B,
Number of fully developed embryos counted in uterus of
PRLR/, PRLR/, and PRLR/RS progesterone-treated
females at d 19.5 of pregnancy. Significance as compared
with control (PRLR/) is indicated (*, P  0.05 by Dunnett’s
multiple comparison post test). C, Ovarian histology of a
4-month-old PRLR/RS transgenic construct shows that by
coexpressing RL, they display normal follicular development;
inset, detail of a preantral follicle. Sections are stained with
hematoxylin-eosin. D, Serum PRL concentration in PRLR/,
PRLR/, and PRLR/RS virgin females. *, P  0.0001; n 
6 for each group.
Fig. 5. Activation of RS Represses Galt Expression and Pro-
moter Activity
A, Galt mRNA levels were measured by RT-PCR in
PRLR/ and PRLR/RS ovaries; L19 was used for loading
control (top). Densitometric analysis (bottom) shows a signif-
icant decrease in Galt mRNA levels in PRLR/RS vs.
PRLR/ ovaries: *, P  0.001, t test. B, Full-length Galt
promoter-reporter construct was transfected together with
increasing concentrations of RS expression vector in UIII
cells. Promoter activity was inhibited by increasing concen-
trations of RS. C, Galt promoter activity is stimulated by PRL
in cells expressing increasing concentrations of RL. D, Ex-
pression of RL reverses the inhibitory effect of PRL through
RS on Galt promoter activity in a concentration-dependent
manner. Significance as compared with control is indicated:
*, P  0.05; **, P  0.01; ***, P  0.001 by Dunnett’s multiple
comparison post test.
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this enzyme (Fig. 5B). Remarkably, when these cells
were transfected with increasing doses of RL expres-
sion vector, a clear RL dose-dependent up-regulation
of the Galt promoter was observed after PRL treat-
ment (Fig. 5C). Moreover, RS-mediated repression of
Galt transcription is reversed by expression of RL
(Fig. 5D).
FOXO3 Expression Is Repressed by PRL
Signaling through RS
The analysis of the full-length mouse Galt promoter
sequence revealed 16 putative forkhead transcription
factor sites, five of them being FOXO3 sites (Fig. 6A).
This attracted our attention because deletion of
FOXO3 gene causes an ovarian defect similar to that
seen in PRLR/RS mice (25, 26) as well as in women
with Galt mutation (24). This finding together with the
fact that FOXO3 regulates transcriptional activity of
genes involved in glucose metabolism (32) led us to
examine whether FOXO3 is repressed by PRL through
RS, and whether FOXO3 regulates Galt transcription.
As shown in Fig. 6B, FOXO3 is profoundly repressed
at mRNA level in the ovaries of PRLR/RS females as
compared with their PRLR/ littermates.
To further examine the PRL-mediated inhibition of
FOXO3, PRLR/RS females were sc injected with
100 l CB-154 (1 g/l 70% ethanol) to block the
endogenously produced PRL. Six hours later, they
were injected ip with 100 l PRL (60 g/100 l saline),
and ovaries were isolated at different times thereafter.
Results shown in Fig. 6C (first lane) indicate that
FOXO3 is highly expressed in the PRLR/RS ovaries
6 h after CB-154 treatment and before PRL adminis-
tration. Injection of PRL induced a drop in FOXO3
protein, and within 2 h of PRL treatment, FOXO3 ex-
pression was almost completely inhibited.
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Fig. 6. Activation of RS Represses FOXO3 Activity
A, Schematic diagram shows putative FOXO3 response elements found in the2879/391-bp Galt promoter sequence (black
arrows). Other forkhead response elements are indicated with gray arrows. The position of each forkhead response element as
well as their core similarity is indicated in the table. B, FOXO3a mRNA levels were measured by RT-PCR in PRLR/ and
PRLR/RS ovaries; L19 was used for loading control. Densitometric analysis (right) shows a significant decrease in FOXO3
mRNA levels in PRLR/RS vs. PRLR/ ovaries: *, P  0.001, t test. C, FOXO3 protein levels were analyzed by Western blot
in ovaries of PRLR/RS and PRL/ females injected with PRL for 0, 15, 30, and 120 min. -Actin was used as an internal loading
control. Densitometric analysis shows that whereas PRL causes in vivo a significant decrease in FOXO3 expression in PRLR/RS
ovaries (top right; *, P  0.001 by Dunnett’s multiple comparison post test), it has no inhibitory effect on FOXO3 protein levels
in PRLR/ ovaries (bottom right, P  0.5).
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We examined whether PRL can repress FOXO3 in
ovaries expressing both RS and RL. For this experi-
ment, PRL null mice were used because they express
both types of receptors but do not produce PRL. As
shown in Fig. 6C, PRL has no detectable effect on
FOXO3 protein levels in the ovaries of these mice. This
suggests that expression of RL may prevent the down-
regulation of FOXO3 induced by PRL signaling
through RS.
FOXO3 Enhances Galt Transcription
To evaluate the role of FOXO3 as a regulator of Galt
transcription, the full-length mouse Galt promoter was
transfected into HepG2 cells in the presence or ab-
sence of either wild-type or constitutively active
FOXO3, also known as triple-mutant nonphosphory-
latable FOXO3 (33). As shown in Fig. 7A, both FOXO3
expression vectors up-regulate Galt promoter activity.
A serial 5-deletion of Galt promoter revealed that the
essential site for FOXO3 stimulation is located be-
tween 613 and 21 bp, a region that contains a
putative FOXO3 site at584 bp (Fig. 7B). Surprisingly,
mutation of 584-bp FOXO3 response element did
not prevent FOXO3-induced stimulation of the pro-
moter. To examine whether this putative FOXO3 site
binds to its cognate transcription factor, EMSAs were
performed using oligonucleotides containing the
584-bp FOXO3 response element either intact or
mutated. The sequence of the FOXO3 consensus
binding site-containing oligonucleotide from the IGF-
binding protein IGFBP-1 gene [termed insulin-respon-
sive sequence (IRS)] was used as a positive control
(33). Incubation of the oligonucleotides with nuclear
extract from HepG2 cells revealed the formation of two
complexes (Fig. 7C). Competition with excess unla-
beled wild-type oligonucleotides and supershift with
anti-FOXO3 antibody indicate the specificity of FOXO3
binding to Galt promoter. Interestingly, mutation of the
584-bp FOXO3 response element did not prevent
the binding of this transcription factor to this piece of
DNA, which suggests that FOXO3 could be stimulating
Galt promoter either by binding to a novel response
element not yet reported or by associating with a
cofactor that binds to Galt promoter, stimulating its
activity. In either case, it is clear from these results that
FOXO3 enhances Galt transcriptional activity.
DISCUSSION
In the present study, we report that mice expressing
only RS, specifically the PR-1 isoform of the receptor,
have a severe ovarian impairment. From the three
short isoforms reported in mouse (8), PR-1 has the
highest homology with the rat and, more importantly,
is the one that shows specific binding of PRL and
mitogenic responsiveness (20). Whether the other two
short isoforms have the same deleterious effect on the
ovary remains to be investigated.
Our data show that PRLR/RS ovaries have a pre-
mature follicular development followed by massive fol-
licular cell death. Although the signaling pathway
downstream of RS still needs to be determined, we
clearly show that PRL signaling through RS represses
FOXO3 and Galt, which are important for normal fol-
licular development. Normally, Galt is highly ex-
pressed in ovaries and liver, which are the major sites
of expression for this enzyme (34). Galt participates in
the metabolism of galactose to glucose (35). Defi-
ciency in Galt activity leads to accumulation of galac-
tose metabolites, which causes ovarian toxicity (27,
34). This toxicity is explained by the synergism of two
metabolites, galactose-1-phosphate and galactitol.
Accumulation of galactose-1-phosphate is thought to
inhibit enzymes involved in glucose metabolism, lead-
ing to deficient glycosylation reactions and decrease
in energy production in the ovarian cells. As to galac-
titol, it is a galactose metabolite that cannot pass
through the cellular membrane, and its accumulation
into the cells causes an osmotic disequilibrium that
C
B
A
Fig. 7. FOXO3 Binds to Galt Promoter and Stimulates Its
Transcriptional Activity
A, The full-length Galt promoter-reporter construct was
transfected in HepG2 cells together with either wild-type
FOXO3 expression vector (WT-FOXO3) or with constitutively
active vector (CA-FOXO3). Significance as compared with
control is indicated: *, P  0.01 by Dunnett’s multiple com-
parison post test. B, 5 serial deletions of Galt promoter show
that the essential region for the stimulatory effect of FOXO3
expression on the luciferase activity is located between613
bp and 21 bp. *, P  0.001. C, Protein-DNA complexes
were analyzed by EMSA using nuclear extract from HepG2
cells and 596/-565-bp oligonucleotide from the Galt pro-
moter containing either the intact (584) or the mutated
FOXO3 (m-584) binding site located at 584 bp. IRS oligo-
nucleotide was used as a positive control for the FOXO3
binding (arrowheads) and supershift (arrow).
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leads to water influx and ultimately to cell death. In
women, either mutations in Galt gene or a deficiency in
enzyme activity causes a disease known as galac-
tosemia associated with POF (27, 30, 34). Young
women with this disease are fertile early in life but
become sterile in their late 20s, displaying ovaries
formed by interstitial cells and devoid of follicles sim-
ilarly to those seen in PRLR/RS mice. Interestingly,
we found the expression of Galt to be down-regulated
by PRL signaling through RS. The analysis of the con-
sensus sites in the Galt promoter pinpointed FOXO3
as a possible modulator of Galt transcription. Indeed,
our data show that FOXO3 markedly enhances Galt
promoter activity. It has been reported that FOXO3 null
mice exhibit premature follicular development at an
early age followed by severe follicular death leading to
ovaries formed by theca/interstitial cells surrounding
collapsed zona pellucida (25, 26). In fact, the reported
ovarian histology of FOXO3 null mice resembles that
of RS-expressing mice at an older age (Fig. 3D). This
association between FOXO3 and Galt may provide an
explanation for the severe follicular death seen in the
FOXO3 null mice. It has been suggested that FOXO3
plays a decisive role in controlling follicular activation
and early development. Overexpression of this tran-
scription factor in oocytes causes retarded oocyte
growth and follicular development (36), whereas the
FOXO3 null females exhibit excessive activation of
primordial follicles followed by massive cell death (25,
26). In addition to regulating enzymes involved in glu-
cose metabolism, FOXO3 is well known to stimulate
genes involved in apoptosis (reviewed in Ref. 37).
However, deletion of FOXO3 gene showed an increase
in ovarian cell death rather than inhibition in the apo-
ptotic process (25, 26). Because Galt is up-regulated
by FOXO3, deletion of this transcription factor may
have decreased Galt expression in the FOXO3 null
ovary, leading to follicular death by galactose toxicity.
We also show in this report that RL can prevent PRL
signaling through RS and protect the ovary from the
deleterious effect of such signaling. The marked inhi-
bition of Galt promoter activity in cells expressing RS
is clearly reversed by coexpression of RL. In addition,
no down-regulation of FOXO3 and Galt is found when
RL is coexpressed with RS, and the ovarian defect
seen in ovaries expressing only RS is no longer ob-
served in RS transgenic mice on either heterozygous
or wild-type background. In fact, in wild-type animals,
both isoforms are expressed in the ovaries, and their
ratio varies along the estrous cycle, suggesting that
the coexpression of both receptors is important for the
normal physiological development of the ovarian folli-
cles. Indeed, RL is expressed at much higher levels
than RS in the growing follicles (9), and this may pre-
vent signaling through RS.
POF is a common cause of infertility and premature
aging in women, with an estimated 1% incidence;
however, the vast majority of cases of POF are idio-
pathic. Although it is not yet clear how PRL signals in
human ovary, the possibility that this disease may be
due, in some patients, to a failure of the RL is intriguing
and deserves further investigation. We have generated
a mouse model for this type of POF and provide an
explanation as to how PRL acting through its short
cognate receptor can lead to POF.
Our findings that activation of RS by PRL represses
FOXO3 and Galt and that FOXO3 stimulates Galt tran-
scriptional activity provide an interesting and novel link
between the POF seen in mice expressing RS and
mice with FOXO3 gene deletion and in women with
Galt mutation.
MATERIALS AND METHODS
Animal Model
RS transgenic females were originally generated by microin-
jecting the eF1-PRLR-PR-1 transgenic construct encoding
the mouse cDNA for RS into fertilized PRLR/ oocytes
derived from 129 Sv pure background mice (20). This con-
struct is driven by the elongation factor 1 promoter, which
makes it ubiquitously expressed in the tissues along all
stages of development. These PRLR/RS females are fer-
tile, and by overexpressing the RS, they can rescue the
mammary development defect displayed by PRLR/ fe-
males (20).
For the present study, we have generated females ex-
pressing only the short form of the prolactin receptor
(PRLR/RS) by mating PRLR/RS females with fertile
PRLR/ males. The PRLR/ females were obtained by
mating PRLR/ females with PRLR/ males.
Animals were identified by RT-PCR on genomic DNA pu-
rified from tail using direct PCR lysis reagent (Viagen Biotech,
Inc., Los Angeles, CA) (Fig. 1). For PRLR gene expression, the
forward primers were 5-GAA GAG CAA GAT CTC AAG
AAC-3 for the wild type and 5-CCA GTC CCT TCC CGC
TTC AGT-3 for the mutated (Neo) strand, and the reverse
primer was 5-GAG AAA AAC ACC TAT GAA TGT-3. For RS
transgenic expression, forward 5-AAG TTC GAC ACA AAC
TCA CA-3 and reverse 5-ACT GAG TGG ACC CAA CGC
AT-3 primers for the human GH terminator present in the
eF1-PRLR-PR-1 transgenic construct were used (Fig. 1).
The cycling parameters for the PRLR consisted of one cycle
of 94 C for 5 min and then 35 cycles of 94 C for 45 sec, 55 C
for 1 min, and 72 C for 45 sec followed by a single cycle of 5
min at 72 C for extension. The molecular size for the wild-type
product is 350 and 580 bp for the mutant. For the RS trans-
genic construct, the cycling parameters were 94 C for 5 min
and then 30 cycles of 94 C for 1 min, 64 C for 1 min, and 72
C for 1 min followed by a single cycle of 5 min at 72 C for
extension, and the molecular size is 750 bp. RT-PCR prod-
ucts were electrophoresed on a 1% agarose gel using
100-bp PCR markers (Invitrogen, Carlsbad, CA) as standards
to determine the molecular size.
Animals were kept under conditions of controlled light
(0700–1900 h) and temperature (22–24 C) with free access to
standard rodent chow and water.
Experimental Animals
All experimental procedures were performed in accordance
with the Guidelines of the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were ap-
proved by the Institutional Animal Care and Use Committee.
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Tissue Preparation and Histology
For histological analysis, cycling females at different ages
were killed at estrus. The ovaries were dissected and either
frozen in liquid nitrogen for RNA and protein extraction or
fixed either in Bouin or 10% formalin for histological exami-
nation. Tissues were serially sectioned (5 m) and stained
with hematoxylin-eosin. Follicular counting was performed in
all sections of each ovary. Follicles that contained oocytes
with clearly visible nuclei were scored, and the total number
of follicles at any particular developmental stage was calcu-
lated as the sum of follicles from all sections of an ovary.
To examine whether the interstitial/thecal tissue left in the
ovaries of mice expressing only RS express P450c17, ovarian
sections were incubated overnight at 4 C with a primary
polyclonal antibody to P450c17 and then incubated with a
secondary biotinylated goat antirabbit IgG according to the
manufacturer’s instructions (Vectastain ABC kit; Vector Lab-
oratories, Burlingame, CA). Peroxidase activity was devel-
oped with Nova Red solution (Vector)
Apoptosis levels were measured by terminal deoxynucle-
otide transferase-mediated nick end-labeling using an
ApopTag Peroxidase In Situ kit (Chemicon International, Te-
mecula, CA) according to the manufacturer’s manual.
Superovulation Protocol and Progesterone
Pellet Implantation
To induce superovulation, PRLR/, PRLR/, and
PRLR/RS female mice were injected ip with 5 IU preg-
nant mare serum [equine chorionic gonadotropin (eCG)]
(Sigma Chemical Co., St. Louis, MO) followed by 5 IU hCG
(Sigma) 48 h later. Ovaries were then isolated for histolog-
ical examination. The difference in the number of released
oocytes was determined by one-way ANOVA followed by
Dunnett’s multiple comparisons post test that allows com-
parisons against a control (wild type).
To determine whether PRLR/ and PRLR/RS females
can maintain pregnancy, they were mated with fertile
PRLR/ males, and the day that a vaginal plug was found,
a progesterone pellet (25 mg; Innovative Research of Amer-
ica, Sarasota, FL) was sc implanted. These females were
maintained until the time of normal parturition. The difference
in the number of fully developed embryos for each genotype
was determined by one-way ANOVA followed by Dunnett’s
multiple comparisons post test.
PRL Hormone Assay
After anesthesia, retroorbital blood samples were taken from
cycling PRLR/, PRLR/RS, and PRLR/ females, and
PRL levels were measured by RIA, at the National Hormone
and Pituitary Program, Harbor-UCLA Medical Center, Tor-
rance, CA. The statistical differences were determined by
one-way ANOVA followed by Dunnett multiple comparisons
post test.
RNA Extraction and RT-PCR
RNA was extracted using TRIzol reagent (Life Technologies,
Rockville, MD) following the manufacturer’s protocol. Ovarian
RNA from 2-month-old females was transcribed into cDNA
by superscript polymerase II. Custom oligonucleotide prim-
ers were obtained from Life Technologies and used to amplify
the appropriate cDNA templates by PCR. Mouse Galt,
FOXO3, and L19 mRNA expression was detected using 5-
CAG TAC CCT TGG GTG CAG AT-3 (forward), 5-TGG TTA
GGA CCA GAC GTT CC-3 (reverse); 5-GTC ATG GGC CAC
GAT AAG TT-3 (forward), 5-GGG CTG CTA ACA GTC TCT
GC-3 (reverse); and 5-AGC GCC TCC AGG CCA AGA
AGG-3 (forward), 5-CCA GGC CGC TAT GTA CAG ACA
CGA-3 (reverse) primers, respectively. PCR product size for
Galt, FOXO3, and L19 were 217, 400, and 100 bp,
respectively.
Conditions for each template were optimized so that sig-
nals were in the linear range of detection. The PCR products
with DNA loading buffer were then separated by gel electro-
phoresis on a 0.7% agarose gel. L19 concentrations were
used as internal control for comparison.
Western Blot Analysis
Total ovary lysates were prepared by homogenizing the tis-
sues in RIPA buffer (1 PBS, 1% Nonidet, 0.5% sodium
deoxycholate, 0.1% SDS) containing 1 M sodium or-
thovanadate, 10 g/ml phenylmethylsulfonyl fluoride, and 30
l/ml aprotinin. Proteins were resolved on 8.5% denaturing
polyacrylamide. After gel electrophoresis, proteins were elec-
trophoretically transferred to a polyvinylidene difluoride
membrane (Millipore Corp., Billerica, MA). The blots were
incubated 1 h at room temperature with 5% nonfat dry milk in
Tris-buffered saline (pH 8.0) containing 0.1% Tween 20. Blots
were washed and incubated overnight at 4 C with the FOXO3
polyclonal antibody (1:1000 dilution; Upstate Biotechnology,
Lake Placid, NY) and then incubated with a secondary anti-
body linked to horseradish peroxidase for 1 h at room tem-
perature. -Actin (Abcam Inc., Cambridge, MA) was used as
internal loading control. Complexes were visualized using the
West Pico chemiluminescence detection kit (Pierce Biotech-
nology, Inc., Rockford, IL).
Microarray Analysis
Total RNA was extracted from 2-month-old PRLR null (con-
trol) and PRLR/RS ovaries using Atlas Glass Total RNA
Isolation Kit and reverse-transcribed with PowerScript re-
verse transcriptase (BD Biosciences, San Diego, CA). cDNA
was labeled with [-33P]dATP (Amersham, Piscataway, NJ),
purified using the Atlas NucleoSpin, and hybridized overnight
at 60 C with Atlas plastic mouse 5K oligo microarrays mem-
branes (BD Biosciences) carrying cDNA probes for approxi-
mately 5000 known mouse genes according to the manufac-
turer’s instructions. Membranes were washed and exposed
to a phosphorimaging screen overnight. The intensity of
spots was analyzed using Atlas Image 2.7 and Atlas Naviga-
tor 2.0 software. The intensity of each gene was averaged
from two individual spots. A cDNA synthesis control was
used as a positive control and for grid template alignment.
The values were normalized using six housekeeping genes
(ubiquitin, tyrosine 3-monooxygenase, ornithine decarboxyl-
ase, glyceraldehyde-3-phosphate dehydrogenase, cytoplas-
mic -actin, and 40S ribosomal protein S29). Genes were
excluded if they were detected in only one spot or at levels
near or below background. Differences over 2-fold in the
intensity of the spots were considered significant.
Cell Lines and Culture
Human hepatic carcinoma cells (HepG2) were obtained from
American Type Culture Collection (Manassas, VA) and cul-
tured in Eagle’s MEM (with Eagle’s balanced salt solution and
L-glutamine) supplemented with 10% fetal bovine serum,
1000 U/ml penicillin G, 2.5 g/ml amphotericin B, 1000 g/ml
streptomycin, 1 mM sodium pyruvate, and 1 nonessential
amino acids. Rat uterine stromal cells (UIII) were cultured in
M199 medium (with phenol red and L-glutamine) supple-
mented with 10% fetal bovine serum, 1000 U/ml penicillin G,
1000 g/ml streptomycin, 1 mM sodium pyruvate, and 1
nonessential amino acids. Cells were incubated in a humid-
ified atmosphere of 5% CO2 at 37 C.
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Galt Promoter Reporter Constructs
The 21/342-bp Galt promoter-reporter truncation was
cloned by PCR from genomic DNA using primers generated
with the Primer3 software (supplemental Table 2). Restriction
sites for SmaI and HindIII were added to the primers. PCR
was performed using 1 g mouse genomic DNA as a tem-
plate. PCR product was cloned into pGEMTeasy (Promega,
Madison WI) according to the manufacturer’s instructions.
After sequencing, it was digested with SmaI and HindIII (dual
digestion in OnePhor All Buffer; Amersham), purified using
the GeneClean II kit (Qbiogene Inc., Irvine, CA) according to
the manufacturer’s instructions, and subcloned in pGL3 ba-
sic luciferase reporter vector (Promega).
To generate the 613/379-bp Galt promoter-reporter
construct, the full-length promoter-construct was digested
with VspI, Klenow blunt-ended (Invitrogen), purified by phenol
extraction, digested with NcoI, and run in a 1.5% agarose gel.
The construct was purified using the GeneClean II kit (Qbio-
gene) and ligated in pGL3 basic luciferase reporter vector
(Promega). Mutation of the putative FOXO3 response ele-
ment located at584 bp of this promoter-reporter truncation
was created using the Stratagene (La Jolla, CA) QuikChange
II kit according to the manufacturer’s instructions and con-
firmed by sequence analysis after cloning into pGEMTeasy
and subcloning into pGL3 basic. Four mutations (underlined
letters) were introduced into the primer with three of them in
the core sequence of the FOXO3 response element (5-GGT
GTG CAC CAC CAC TGG CCG TTC CAT CTA CTT TTA TAT
AGA TTG GGC C-3).
The 2879/391-bp mouse Galt promoter sequence was
scanned with the MatInspector professional 7.4 software
(available at the website http://www.genomatix.de/) using
0.75 for the core similarity and 0.8 for the matrix similarity in
the matrix group for vertebrates.
Transient Transfections and Constructs
HepG2 cells were cotransfected with either full-length, trun-
cated, or mutated mouse Galt promoter-reporter construct in
pGL3basic and either wild-type or constitutively active
FOXO3 (CA-FOXO3) in pAltermax expression vector using
CaPO4 as transfection method. Cells were harvested 24 h
after transfection. In all transfections, the total amount of
DNA was balanced with the appropriate empty vector. Each
experiment was performed at least three times in triplicate.
Data are expressed as means SEM and analyzed by one- or
two-way ANOVA.
UIII cells were cotransfected with Galt promoter-reporter
construct and with either RL or RS in pcDNA expression
vectors using Lipofectamine 2000 (Invitrogen) as transfection
method. Immediately after transfection, cells were treated for
24 h with PRL (1 g/ml) and harvested. Each experiment was
performed at least three times in triplicate. Data are ex-
pressed as means  SEM and analyzed by two-way ANOVA.
EMSA
To prepare nuclear extracts, HepG2 and UIII cells were
scraped from 75-cm2 flasks with ice-cold PBS (Ca2 and
Mg2 free) containing 1 proteases inhibitor cocktail (Sigma)
and pelleted. The pellet was resuspended for 10 min in 1 ml
hypotonic buffer RBS [10 mM NaCl, 3 mM MgCl2, 10 mM Tris
(pH 7.4), 0.5% Nonidet NP-40, and proteases inhibitors]. The
tubes were vortexed for 30 sec and centrifuged at 3000  g
for 5 min. The resulting pellet was resuspended in 50 l
extraction buffer C [420 mM KCl, 20 mM HEPES (pH 7.9), 1.5
mM MgCl2, 0.2 mM EDTA, 20% glycerol, and proteases
inhibitors), rocked at 4 C for 20 min, and incubated on ice
for 30 min. The supernatants were aliquoted and frozen at
80 C.
For the EMSA, IRS-containing oligonucleotide (5-ATT
GCT AGC AAG CAA AAC AAA CCG CTA GCT TA-3) as well
as wild-type and mutated 584-bp FOXO3 putative binding
site-containing oligonucleotides (5-CAC TGG CCG TTT GGT
TTA CTT TTA TAT AGA TT3- and 5-CAC TGG CCG TTC
CAT CTA CTT TTA TAT AGA TT-3, respectively, with the
underlined letters showing the mutation positions) were end-
labeled with [-32P]ATP (Amersham). Nuclear extracts (1 g)
were incubated for 30 min in binding buffer together with 1 
105 cpm labeled oligonucleotides. Six micrograms FOXO3
antibody (Upstate) were added to binding buffer for the su-
pershift. Samples were electrophoresed for 2.5 h on 4%
nondenaturing polyacrylamide gels. Gels were dried and ex-
posed to x-ray film for 18–48 h.
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